Corvus Pharmaceuticals is a clinical-stage biopharma company developing first-in-class agents that target the immune system to treat patients with cancer.

Corvus Pharmaceuticals, Inc.
[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”CRVS” api=”yf” style=”font-size: 15px”]
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttps://www.corvuspharma.com
Founded2014
Disease Focus
Development Stage
STOCK CODENASDAQ: CRVS
Address863 Mitten Road, Suite 102, CA 094010BurlingameUnited States
863 Mitten Road, Suite 102, CA 094010
Burlingame
United States
Contact Number+1 650 900 4520
+1 650 900 4520
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/corvus-pharmaceuticals” connections=”true” suffix=””]
Corvus Pharmaceuticals drug development technology platform is based on, Immune checkpoints and Reprogramming T cells.
In Jul 2015, Corvus Pharmaceuticals raised $33.5 Mn in series A financing round while in Sep. 2015 company raised $75 Mn in series B financing round.